| TEAM | techniques for effective alcohol management; Training in Expanded Auxiliary Management; transfemoral... |
|---|---|
| MDIS | medical diagnostic imaging support; medical diagnostic imaging system |
| PDC | parkinsonism dementia complex; pediatric cardiology; penta-decylcatechol; phosducin; physical depend... |
| MEDAC Syndrome | Multiple-Endocrine Deficiency Autoimmune-Candidiasis |
| AEP | acute edematous pancreatitis; artificial endocrine pancreas; auditory evoked potential; average evok... |
| multiple endocrine neoplasia 1 | <radiology> Multiple endrocrine neoplasia syndrome three P's. Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%). Synonym: Wermer syndrome (12 Dec 1998) |
|---|---|
| multiple endocrine neoplasia 2 | <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia Synonym: Sipple syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 3 | <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B Synonym: Schimke, marfanoid syndrome (12 Dec 1998) |
| multiple endocrine neoplasia type 1 | A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients. (12 Dec 1998) |
| multiple endocrine neoplasia type 2 | <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. (27 Sep 1997) |
| multiple endocrine neoplasia type 2a | A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands. (12 Dec 1998) |
| multiple endocrine neoplasia type 2b | A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas. (12 Dec 1998) |
| neoplastic endocrine-like syndromes | Endocrine syndromes due to hormone production by neoplasms of non-endocrine tissue, or by other than the usual endocrine tissues. They are often the first indication of a previously undetected neoplasm. (12 Dec 1998) |
| endocrine | Pertaining to internal secretions, hormonal. Compare: exocrine. Origin: Gr. Krinein = to separate (18 Nov 1997) |
| endocrine cells of gut | Cells found throughout the lining of the gastrointestinal tract that contain regulatory peptide hormones and/or biogenic amines. The substances are located in secretory granules and act in an endocrine or paracrine manner. Some of these substances are also found in neurons in the gut. There are at least 15 different types of endocrine cells of the gut. Some take up amine precursors and have been called apud cells. However, most endocrine cells of the gut apparently have endodermal rather than neuroectodermal origin, so the relationship with apud cells is not clear. (12 Dec 1998) |
| endocrine disorders | Disorders which involve the over-production or under-production of hormone substances from an endocrine gland. Some examples include diabetes, hypothyroidism, hyperthyroidism, hyperparathyroidism, Cushing's disease, Cushing's syndrome and acromegaly. (27 Sep 1997) |
| endocrine exophthalmos | Exophthalmos associated with thyroid gland disorders. See: Graves' ophthalmopathy, Graves' orbitopathy. (05 Mar 2000) |
| endocrine gland | Organs or gland that secrete regulatory substances directly into the circulation and not through a duct. Examples are pituitary, thyroid, parathyroid, adrenal glands, ovary and testis, placenta and beta cells of pancreas. (27 Sep 1997) |
| endocrine gland neoplasms | Tumour or cancer of the endocrine glands in general or unspecified. (12 Dec 1998) |
| endocrine glands | Ductless glands that secrete substances which are released directly into the circulation and which influence metabolism and other body functions. (12 Dec 1998) |